ArticlePDF Available

Disseminated cryptococcosis with meningitis, peritonitis, and cryptococcemia in a HIV-negative patient with cirrhosis: A case report

Authors:

Abstract and Figures

Cryptococcus neoformans is an encapsulated yeast that causes serious infections in immunocompromised populations. The majority of cases occur in HIV-infected individuals. Disseminated disease is uncommon, and very rarely includes peritonitis. We report a case of a 41-year-old, HIV-negative, Caucasian man with alcoholic liver cirrhosis who presented with fever and seizure. Disseminated cryptococcosis with meningitis, peritonitis, and cryptococcemia was diagnosed, and despite adequate treatment the patient developed multi-system organ failure and eventually expired. Disseminated cryptococcosis, particularly with peritonitis, is an uncommon manifestation of Cryptococcus neoformans infection. Liver cirrhosis serves as a risk factor for disseminated disease in HIV-negative patients. A high clinical suspicion and early initiation of therapy is needed to recognize and treat patients effectively.
Content may be subject to copyright.
BioMed Central
Page 1 of 4
(page number not for citation purposes)
Cases Journal
Open Access
Case Report
Disseminated cryptococcosis with meningitis, peritonitis, and
cryptococcemia in a HIV-negative patient with cirrhosis: a case
report
Baligh Ramzi Yehia*, Michael Eberlein, Stephen D Sisson and David N Hager
Address: Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 9020, Baltimore, Maryland,
USA
Email: Baligh Ramzi Yehia* - byehia@jhmi.edu; Michael Eberlein - meberle3@jhmi.edu; Stephen D Sisson - ssisson@jhmi.edu;
David N Hager - dhager1@jhmi.edu
* Corresponding author
Abstract
Introduction: Cryptococcus neoformans is an encapsulated yeast that causes serious infections in
immunocompromised populations. The majority of cases occur in HIV-infected individuals.
Disseminated disease is uncommon, and very rarely includes peritonitis.
Case presentation: We report a case of a 41-year-old, HIV-negative, Caucasian man with
alcoholic liver cirrhosis who presented with fever and seizure. Disseminated cryptococcosis with
meningitis, peritonitis, and cryptococcemia was diagnosed, and despite adequate treatment the
patient developed multi-system organ failure and eventually expired.
Conclusion: Disseminated cryptococcosis, particularly with peritonitis, is an uncommon
manifestation of Cryptococcus neoformans infection. Liver cirrhosis serves as a risk factor for
disseminated disease in HIV-negative patients. A high clinical suspicion and early initiation of
therapy is needed to recognize and treat patients effectively.
Introduction
Cryptococcus neoformans is a ubiquitous encapsulated yeast
that predominately causes significant infections in immu-
nocompromised individuals, with eighty to ninety per-
cent of all cases occurring in those with HIV infection
[1,2]. The most common sites of infection are the central
nervous system (CNS) and lungs [1-4]. Disseminated dis-
ease is uncommon and when present almost always
occurs in HIV-infected patients [2]. Cryptococcal peritoni-
tis occurs even less frequently then disseminated disease
and is considered a rare manifestation of cryptococcosis
[1]. Here, we present a case of disseminated cryptococco-
sis with meningitis, peritonitis, and cryptococcemia
occurring in a HIV-negative patient with alcoholic liver
cirrhosis.
Case presentation
A 41-year-old Caucasian man presented to the emergency
department with a 1-month history of jaundice, halluci-
nations, and ataxia. He was initially treated for acute alco-
holic hepatitis with pentoxifylline and steroids, hepatic
encephalopathy with lactulose, and started on empiric
therapy for spontaneous bacterial peritonitis (SBP) with
ceftriaxone. His mental status returned to baseline, but he
Published: 28 October 2009
Cases Journal 2009, 2:170 doi:10.1186/1757-1626-2-170
Received: 19 October 2009
Accepted: 28 October 2009
This article is available from: http://www.casesjournal.com/content/2/1/170
© 2009 Yehia et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cases Journal 2009, 2:170 http://www.casesjournal.com/content/2/1/170
Page 2 of 4
(page number not for citation purposes)
continued to have worsening liver and renal failure. Hepa-
torenal syndrome was diagnosed and he was started on
octreotide, midrodine and albumin.
His medical history was notable for an ischemic stroke
with mild residual deficit, gastric bypass surgery, uncom-
plicated lumbar spinal fusion surgery, and alcohol
induced cirrhosis of the liver. Social history suggested that
he consumed approximately one pint of vodka per day.
Family history was noncontributory. He was not taking
any medications at home.
On hospital day 22, he sustained a tonic-clonic seizure,
which lasted 4 minutes. Given his prolonged post-ictal
state and low blood pressure he was transferred to the
intensive care unit (ICU). Evaluation at that time revealed
a severely obtunded and jaundiced man. Vital signs
showed a temperature of 38.4°C, heart rate of 92 beats/
min, blood pressure of 109/62, and respiratory rate of 19
breaths/min. Oxygen saturation by pulse oximetry was
95% on room air. Head and neck examination revealed
scleral icterus and a supple neck. Diffuse coarse crackles
were noted on auscultation of the chest. The cardiac
rhythm was regular with a normal rate. No murmurs were
appreciated. His abdomen was markedly distended, con-
sistent with ascites. Guarding, rebound tenderness, and
organomegaly were not appreciated. Neurologic examina-
tion revealed sluggish pupils, a weak gag reflex, and move-
ment of the extremities only in response to painful
stimuli. No asymmetry was appreciated.
Laboratory studies were obtained and revealed a white
blood cell (WBC) count of 62 × 103 cells/mm3, with 89%
polymorphonucleated cells (PMNs), and a platelet count
of 112 × 103 per mm3. His INR was 1.5. An extended met-
abolic and liver panel demonstrated: sodium 127 mEq/L,
BUN 63 mg/dL, creatinine 6.8 mg/dL, total bilirubin 39.8
mg/dL, AST 201 U/L, ALT 109 U/L, and alkaline phos-
phatase 349 U/L. Ammonia was 38 μmol/L. Arterial
blood gas showed a pH of 7.33, PCO2 of 35 mm Hg, PO2
of 184 mm Hg, and HCO3 concentration of 15 mEq/L on
40% oxygen. HIV antibody was found to be negative and
HIV-1 RNA undetectable.
Given his seizure, fever, and leukemoid reaction, he was
started on empiric therapy with cefepime, vancomycin,
ampicillin, and acyclovir. Levetiracetam (Keppra) was ini-
tiated for seizure control. An MRI of the brain was nega-
tive for any evidence of intracranial bleeding or other
space occupying lesions. An EEG was unremarkable. Lum-
bar puncture was attempted, but unsuccessful due to the
patient's prior spine surgery. Paracentesis revealed ascitic
fluid with a WBC of 797 per mm3 with 81% PMNs,
despite therapy with ceftriaxone. Ascites gram stain, bacte-
rial and fungal cultures were negative. Because of his pro-
gressive clinical deterioration amphotericin was added to
his regimen on hospital day 23.
Lumbar puncture under fluoroscopy was performed on
hospital day 24 and cerebrospinal fluid (CSF) analysis
revealed 104 WBCs per mm3 with 98% PMNS, glucose 47
mg/dL, and protein 84 mg/dL. CSF gram stain demon-
strated yeast and culture grew Cryptococcus neoforman (Fig-
ure 1). CSF cryptococcal antigen was also positive.
Though initially negative, blood cultures also grew C. neo-
formans. Flucytosine was added to his medical regimen for
better CSF coverage.
The patient was diagnosed with disseminated cryptococ-
cosis with meningitis, peritonitis, and cryptococcemia.
Meningitis and cryptococcemia, as demonstrated by posi-
tive Cryptococcus neoformans cultures, and peritonitis,
based on peritoneal fluid leukocytosis in the setting of
low suspicion for SBP. The leukemoid reaction was attrib-
uted to alcoholic hepatitis, as cryptococcemia is not a
known cause and no other infections were identified.
Unfortunately, the patient continued to deteriorate with
refractory hypotension and multi-system organ failure.
Given his overall clinical picture and poor prognosis, the
patient's family ultimately elected to withdraw life sup-
porting measures. The patient expired soon thereafter.
Discussion
Cryptococcus neoformans is an encapsulated yeast that pre-
dominately affects immunocomprimised individuals. In
addition to HIV infection, immunosuppressive medica-
tions, solid-organ transplantation, chronic organ failure
(renal and liver), hematologic malignancy, chronic lung
disease, and rheumatologic disorders can also predispose
individuals to this infection [3].
Meningoenecephalitis and pulmonary infiltrates are the
two most common manifestations of cryptococcal disease
[1,2,5]. Disseminated cryptococcosis is defined by 1) a
positive culture from at least two different sites, or 2) a
positive blood culture [5]. In a series of 33 HIV-negative
patients with disseminated disease, cirrhosis was the most
frequent predisposing condition and was associated with
a grave prognosis [5,6]. Leukocyte impairment, comple-
ment dysfunction, and decreased opsonin activity are
believed to predispose cirrhotic patients to cryptococcosis
[1].
Cryptococcal peritonitis is an unusual manifestation of C.
neoformans [1]. Infection of ascitic fluid accounts for less
than 5% of all cryptococcosis cases in HIV-negative
patients [1,4-6]. When liver cirrhosis is jointly considered,
the prevalence of cryptococcal peritonitis is exceedingly
rare [1,4-6]. Our literature review only identified 19 cases
Cases Journal 2009, 2:170 http://www.casesjournal.com/content/2/1/170
Page 3 of 4
(page number not for citation purposes)
of cryptococcal peritonitis in HIV-negative patients with
liver cirrhosis [1,4-6].
The clinical presentation of disseminated cryptococcosis
is variable and depends on the organ systems involved. C.
neoformans has been identified in cultures from blood,
CSF, sputum, ascites, urine, bone marrow, and skin [2,5].
A diffuse maculo-papular rash may be an important diag-
nostic clue indicating disseminated disease [7]. Central
nervous system (CNS) involvement is the most common
manifestation of disseminated cryptococcosis [5]. Patients
often present in a subacute manner with headache and
fever. Other symptoms can include seizures, confusion,
dementia, and bizarre behavior. Cerebral edema leading
to elevated intracranial pressure can cause blurred vision,
diplopia, confusion, hearing loss, and severe headaches
[8]. In patients with cryptococcal peritonitis, diagnosis
can often be delayed due to lack of specific signs and
symptoms and low clinical suspicion among healthcare
providers [1]. Abdominal pain, increased abdominal
girth, fever, and dyspnea are typical complaints of patients
with cryptococcal peritonitis [1,4].
In patients with CNS disease, imaging of the brain is usu-
ally unremarkable and lumbar puncture is often necessary
to establish the diagnosis. CSF analysis typically reveals a
lymphocytic pleocytosis with elevated protein and
decreased glucose. Opening pressure during lumbar punc-
ture is often elevated to values greater than 20 cm H2O [8].
India ink staining will identify C. neoformans in the CSF of
patients with HIV greater than 90% of the time and in
more than 50% of infected patients without HIV [9]. The
CSF cryptococcal antigen is almost universally positive in
established CNS infection, but may be negative very early
in a patient's clinical course [8,9]. Similar to CNS infec-
tion, diagnosis of peritoneal disease relies on analysis of
ascites fluid and not imaging studies. Diagnosis can be
difficult, requiring multiple ascites fluid samples and pro-
longed culture time [10]. Ascitic fluid usually demon-
strates a low protein level and moderately elevated WBC
Lactophenol Cotton Blue stain of CSF culture noted encapsulated yeast consistent with Cryptococcus neoformans (× 100, × 400)Figure 1
Lactophenol Cotton Blue stain of CSF culture noted encapsulated yeast consistent with Cryptococcus neoform-
ans (× 100, × 400).
Publish with BioMed Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cases Journal 2009, 2:170 http://www.casesjournal.com/content/2/1/170
Page 4 of 4
(page number not for citation purposes)
count [1]. Cryptococcal antigen testing can be performed
on ascites fluid, although limited studies exist on its use
and utility [1]. The diagnostic gold standard for C. neofor-
mans infection is growth of the organism in culture from
an otherwise sterile site [8,9].
Treatment regimens are determined by anatomic site of
infection and host immune status. Though no specific
guidelines exist for the treatment of cryptococcal peritoni-
tis, recommendations for the treatment of CNS disease are
well established [11]. Immunocompetent patients with
cryptococcal meningitis should be treated with amphoter-
icin B and flucytosine for 6-10 weeks, or amphotericin B
and flucytosine for 2 weeks followed by fluconazole (400
mg/d) for a minimum of 10 weeks [11]. For immunosup-
pressed patients without HIV infection, it is recom-
mended that cryptococcal meningitis be treated with
amphotericin B +/- flucytosine for 2 weeks followed by 8-
10 weeks of fluconazole (400-800 mg/d), and then fluco-
nazole (200 mg/d) for an additional 6-12 months [11].
Patients with isolated cryptococcal meningitis typically
improve with appropriate therapy. Depressed levels of
consciousness, high CSF cryptococcal antigen titer, and
cryptococcemia are associated with a poor prognosis [9].
An opening pressure greater than 25 cm H2O is the most
important prognostic factor and is associated with
increased morbidity, including diminished mental capac-
ity, vision loss, cranial nerve palsies, and hydrocephalus
[8]. Prognosis for HIV-negative patients with dissemi-
nated cryptococcosis and liver cirrhosis is poor, with 30
day mortality documented at 100% in one study [5]. In
patients with cryptococcemia, liver cirrhosis was the
strongest independent predictor of 30-day morality (haz-
ard ratio 16.3, 95% CI 2.6-101.7, p = 0.003), even when
compared to HIV infection [6].
Conclusion
In summary, disseminated cryptococcosis, particularly
with peritonitis, is an uncommon manifestation of C. neo-
formans infection. Liver cirrhosis serves as a risk factor for
disseminated disease in HIV-negative patients and is asso-
ciated with a grave prognosis. A high clinical suspicion
and early initiation of therapy is needed to recognize and
treat patients effectively.
Consent
Unfortunately, the patient expired and despite multiple
attempts to contact the family, the next of kin was not
available. The patient case is presented anonymously, and
there is no reason to think that the patient or their family
would object to publication.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BY, ME, and DH were involved in the direct care of the
patient, and contributed to the literature search, data col-
lection, data analysis, and manuscript preparation. SS was
involved in the literature search, data analysis, and manu-
script preparation. All authors have read and approve of
the submitted manuscript.
Acknowledgements
The authors would like to thank Norman J Barker, M.S. and the Pathology
Photography Laboratory at Johns Hopkins University for their assistance.
References
1. Albert-Braun S, Venema F, Bausch J, Hunfeld KP, Schafer V: Crypto-
coccus neoformans peritonitis in a patient with alcoholic cir-
rhosis: case report and review of the literature. Infection 2005,
33(4):282-288.
2. Kokturk N, Ekim N, Kervan F, Arman D, Memis L, Caglar K, Kalkanci
A, Demircan S, Kurul C, Akyurek N: Disseminated cryptococco-
sis in a human immunodeficiency virus-negative patient: a
case report. Mycoses 2005, 48(4):270-274.
3. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster
DJ, Henderson H, Kauffman CA, Haas DW, Saccente M, Hamill RJ,
Holloway MS, Warren RM, Dismukes WE: Cryptococcosis in
human immunodeficiency virus-negative patients in the era
of effective azole therapy. Clin Infect Dis 2001, 33(5):690-699.
4. Kiertiburanakul S, Wirojtananugoon S, Pracharktam R, Sungkan-
uparph S: Cryptococcosis in human immunodeficiency virus-
negative patients. Int J Infect Dis 2006, 10(1):72-78.
5. Chuang YM, Ho YC, Chang HT, Yu CJ, Yang PC, Hsueh PR: Dissem-
inated cryptococcosis in HIV-uninfected patients. Eur J Clin
Microbiol Infect Dis 2008, 27(4):307-310.
6. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, Hung
CC, Luh KT: Cryptococcaemia: clinical features and prognos-
tic factors. QJM 2002, 95(8):511-518.
7. Licci S, Narciso P: Disseminated cryptococcosis in an HIV-neg-
ative patient. Int J Infect Dis 2009, 13(3):e139-140.
8. Johns Hopkins HIV guide [http://www.hopkins-hivguide.org/]
9. Satishchandra P, Mathew T, Gadre G, Nagarathna S, Chandramukhi A,
Mahadevan A, Shankar SK: Cryptococcal meningitis: Clinical,
diagnostic and therapeutic Tttt. Clin Infect Dis 2000,
30(4):710-718.
10. Park WB, Choe YJ, Lee KD, Lee CS, Kim HB, Kim NJ, Lee HS, Oh
MD, Choe KW: Spontaenous cryptococcal peritonitis in
patients with liver cirrhosis. Am J Med 2006, 119:169-171.
11. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly
WG, Sobel JD, Dismukes WE: Practice guidelines for the man-
agement of cryptococcal disease. Infectious Diseases Society
of America. Clin Infect Dis 2000, 30(4):710-718.
... An immunodeficient state associated with Cryptococcus is liver cirrhosis, which was the likely risk factor of our patient. There are various Cryptococcal presentations in cirrhotic patients, including meningitis, pneumonia, peritonitis, pleuritis, and disseminated infection [7,8,[11][12][13][14][15]. We present a case of disseminated Cryptococcus infection who initially presented with a transudative pleural effusion that was antigen-positive and culture-positive for C. neoformans. ...
... Disseminated Cryptococcosis is based on positive cultures from any two organ sites or positive blood culture [12,13,16]. Our patient's pleural fluid, peritoneal fluid, cerebral spinal fluid (CSF), and blood grew C. neoformans at various points in time (Fig. 2). ...
... The immunocompromised state that cirrhotic patients experience is called cirrhosis-associated immune dysfunction (CAIDS). CAIDS denotes systemic failure of innate and adaptive immunity [4,12,13,17,18]. This immune dysfunction could explain how subclinical Cryptococcal pneumonia and pleural effusion seen in our patient proceeded quickly to disseminate infection. ...
Article
Full-text available
To our knowledge, this is the first case report of a transudative pleural effusion with positive Cryptococcal antigen and culture. We describe a 32-year-old male with end-stage liver disease (ESLD) who presented to an outside hospital with dyspnea and a large pleural effusion. An initial pleural fluid analysis was positive for Cryptococcal Ag. However, the infection was eventually found to be widespread as he had positive Cryptococcal Ag and cultures in his pleural fluid, serum, and cerebrospinal fluid (CSF). His antimicrobial regiment was escalated from fluconazole to amphotericin B and flucytosine. His medical condition deteriorated, and the patient passed away. Due to its rarity and range of clinical severity, diagnosis of disseminated Cryptococcosis can be delayed. We present this case to bring awareness of this diagnosis as a differential in immunocompromised patients regardless of a transudative pleural effusion.
... [1][2][3] Cryptococcal dissemination can affect most organs (lungs and meninges more than other sites), and risk factors for disseminated infection include lymphoid malignancies, chronic corticosteroid use, solid organ transplantation, sarcoid, and liver cirrhosis. [4][5][6][7][8][9] C. neoformans causing spontaneous fungal peritonitis is a rare disease process associated with underlying end-stage liver disease and cirrhosis. 1,8 ...
... Our review resulted in 16 articles and 21 cases of cryptococcal peritonitis in HIV-negative patients (Table 1). 1,5,6,[8][9][10][11][12][13][14][15][16][17][18][19][20] Most patients were men (n ¼ 14, 67%) with a median age of 54 years (range, 34-65). Alcohol abuse was the most common cause of underlying cirrhosis (n ¼ 10, 48%), with or without concomitant viral hepatitis. ...
Article
Disseminated Cryptococcus neoformans infection rarely causes peritonitis in non–HIV-infected patients but does affect cirrhotic patients. Diagnostic challenges delay treatment, and mortality is high. We performed a literature search of proven cryptococcal peritonitis cases in HIV-negative adults with underlying cirrhosis, included our own case, and collected demographic, infection risk factor, diagnostic, treatment, and outcomes data. We identified 16 articles and 21 cases. Most patients were men. Alcohol abuse was the leading cause of underlying cirrhosis (n = 10, 48%). Eight (38%) patients experienced an upper gastrointestinal bleed (UGIB) within a month before peritonitis presentation. Peritoneal fluid analysis was abnormal and lymphocytic predominant. Half the patients were fungemic. When performed, peritoneal fluid cryptococcal antigen (CrAg) test results were positive. Amphotericin B was the primary treatment. Mortality was high at 76%. In conclusion, C. neoformans is an opportunistic pathogen that causes peritonitis in non-HIV, cirrhotic patients. People with recent UGIB seem to be at risk. Cryptococcus species infection should be suspected in patients with clinical signs and symptoms of spontaneous bacterial peritonitis whose lymphocytic-predominant peritoneal fluid and cultures are negative for bacterial growth. Peritoneal CrAg testing expedites diagnosis because growth on fungal media is slow. Mortality remains high, despite standard therapy with amphotericin B.
... In humans, cryptococcosis is one of the most common opportunistic diseases in immunosuppressed patients (Shourian & Qureshi, 2019) and patients who have experienced organ transplantation or who are affected by lupus, cancer, and diabetes (Maziarz & Perfect, 2016;Ponzio & Chen, 2019;Yehia & Eberlein, 2009). Thus, due to the importance in human medicine, studies in guinea pigs with the purpose of the experimental model are also developed, such as the studies carried out by Riera, Masih, and Nobile (1983), Van Cutsem et al., (1987), Kirkpatrick et al. (2007) and Diamond (1977). ...
Article
Full-text available
Cryptococcus spp affects mainly dogs and cats, however, there are reports in other animal species, such as guinea pigs. The objective of this study is to report a case of a lesion by cryptococcosis in a guinea pig's auricles. The animal had firm nodules under the touch in both auricles, being one of them with a granulomatous aspect, both ulcerated, with serosanguineous secretion, pain, and associated itching. For the diagnosis, a biopsy was performed for histopathological examination and after a result suggestive of fungal dermatitis by Cryptococcus spp., treatment with itraconazole and adjuvant therapy with Echinacea angustifolia 6CH and Carduus marianus 6CH was initiated, which demonstrated to be effective. Furthermore, we suggest the inclusion of cryptococcosis as a differential diagnosis in cases of auricular lesions in this species.
... Cryptococcus neoformans predominately causes significant infections in immunocompromised individuals, 80% to 90% of which are seen in HIV infected individuals. 4 Two of the 3 patients discussed in this case series were HIV infected. However, cryptococcal infection is not unusual in immunocompetent patient as was evident in case 2. This was also apparent in some of the previously reported breast cases. ...
Article
Full-text available
Breast masses in clinical practice are often investigated primarily for neoplastic conditions. Breast fungal infections are unusual, and few cases have been reported in the literature. The differential diagnosis for a breast mass should not be limited to neoplastic conditions as there are treatment implications. The correct diagnosis is associated with reduced and unwanted cases of surgical intervention. We describe 3 cases of cryptococcal infection of the breast that clinically masqueraded as breast malignancies.
... Cryptococcosis is a systemic mycosis that affects a wide variety of mammalian hosts [1]. Most human cases are opportunistic, with risk factors including infection by the acquired immunodeficiency virus (HIV), organ transplantation, lupus, cancer, diabetes, and alcoholism [2][3][4]. These cases are usually caused by members of the Cryptococcus neoformans species complex, which is a cosmopolitan agent. ...
Article
Full-text available
Cryptococcosis is a systemic fungal disease acquired from contaminated environments with propagules of the basidiomycetous yeasts of the Cryptococcus neoformans and C. gattii species complexes. The C. neoformans species complex classically comprises four major molecular types (VNI, VNII, VNIII, and VNIV), and the C. gattii species complex comprises another four (VGI, VGII, VGIII, and VGIV) and the newly identified molecular type VGV. These major molecular types differ in their epidemiological and ecological features, clinical presentations, and therapeutic outcomes. Generally, the most common isolated types are VNI, VGI, and VGII. The epidemiological profile of cryptococcosis in domestic cats is poorly studied and cats can be the sentinels for human infections. Therefore, the present study aimed to determine the molecular characterization of Cryptococcus spp. isolated from domestic cats and their dwellings in the metropolitan area of Rio de Janeiro, Brazil. A total of 36 Cryptococcus spp. strains, both clinical and environmental, from 19 cats were subtyped using multilocus sequence typing (MLST). The ploidy was identified using flow cytometry and the mating type was determined through amplification with specific pheromone primers. All strains were mating type alpha and 6/36 were diploid (all VNII). Most isolates (63.88%) were identified as VNII, a rare molecular type, leading to the consideration that this genotype is more likely related to skin lesions, since there was a high percentage (68.75%) of cats with skin lesions, which is also considered rare. Further studies regarding the molecular epidemiology of cryptococcosis in felines are still needed to clarify the reason for the large proportion of the rare molecular type VNII causing infections in cats.
... Furthermore, bilaterality, and other organ infection suggested a disseminated disorder in our patient. Disseminated cryptococcosis is defined by (1) a positive culture from at least 2 different sites, or (2) a positive blood culture [15] . Cryptococcal infection in other organs was reported; however, cryptococcal mastitis is extremely rare. ...
Article
Full-text available
There have been few reports on the imaging characteristics of cryptococcus neoformans (C. neoformans) infection of the breast. Herein, we reported the imaging features of C. neoformans infection of the breast in a 41-year-old woman with immune thrombocytopenic purpura. Bilateral, diffuse, hyperechoic, and well-defined margin lesions were observed on breast ultrasounds. In addition, a global asymmetry in the left breast, and a focal asymmetry in the right breast were observed on mammograms. Breast fine needle aspiration and biopsy results revealed a C. neoformans infection. After 5 months of treatment with oral fluconazole and amphotericin B, the lesion on the right breast disappeared on repeated-breast ultrasounds.
Article
Full-text available
Background Emerging fungal pathogens pose important threats to global public health. The World Health Organization has responded to the rising threat of traditionally neglected fungal infections by developing a Fungal Priority Pathogens List (FPPL). Taking the highest-ranked fungal pathogen in the FPPL, Cryptococcus neoformans , as a paradigm, we review progress made over the past two decades on its global burden, its clinical manifestation and management of cryptococcal infection, and its antifungal resistance. The purpose of this review is to drive research efforts to improve future diagnoses, therapies, and interventions associated with fungal infections. Methods We first reviewed trends in the global burden of HIV-associated cryptococcal infection, mainly based on a series of systematic studies. We next conducted scoping reviews in accordance with the guidelines described in the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews using PubMed and ScienceDirect with the keyword Cryptococcus neoformans to identify case reports of cryptococcal infections published since 2000. We then reviewed recent updates on the diagnosis and antifungal treatment of cryptococcal infections. Finally, we summarized knowledge regarding the resistance and tolerance of C. neoformans to approved antifungal drugs. Results There has been a general reduction in the estimated global burden of HIV-associated cryptococcal meningitis since 2009, probably due to improvements in highly active antiretroviral therapies. However, cryptococcal meningitis still accounts for 19% of AIDS-related deaths annually. The incidences of CM in Europe and North America and the Latin America region have increased by approximately two-fold since 2009, while other regions showed either reduced or stable numbers of cases. Unfortunately, diagnostic and treatment options for cryptococcal infections are limited, and emerging antifungal resistance exacerbates the public health burden. Conclusion The rising threat of C. neoformans is compounded by accumulating evidence for its ability to infect immunocompetent individuals and the emergence of antifungal-resistant variants. Emphasis should be placed on further understanding the mechanisms of pathogenicity and of antifungal resistance and tolerance. The development of novel management strategies through the identification of new drug targets and the discovery and optimization of new and existing diagnostics and therapeutics are key to reducing the health burden.
Article
Full-text available
Cryptococcal infections (Cryptococcosis) are fatal fungal infections typically caused by Cryptococcus neoformans, a saprophyte frequently found in soil contaminated with pigeon droppings and frequently seen in immunocompromised (specifically HIV Positive) individuals. Now a day’s awareness is emerging on cryptococcal disease among non-immunocompromised patients also. We present a case of Cryptococcus meningitis (CM) in a patient with cardiopulmonary arrest. A 55 year old male patient came with history of headache and fever with neck rigidity since last 3 months. The patient was admitted as a case of CM based on clinical findings and radiological features. Investigations were done to rule out other disorders of the immune system. He was treated with Amphotericine B (IV) and Fluconazole orally for 2 weeks. Culture of CSF was done which showed presence of Cryptococcus neoformans. It is concluded from the findings that Cryptococcus may also affect non-HIV patients regardless to their immune system.
Article
Background Liver cirrhosis is associated with immune deficiency, which causes these patients to be susceptible to various infections, including cryptococcus infection. Mortality in cirrhotic patients with cryptococcosis has increased. The present study was to explore the risk factors of mortality and the predictive ability of different prognostic models. Methods Forty-seven cirrhotic patients with cryptococcosis at a tertiary care hospital were included in this retrospective study. Data on demographics, clinical parameters, laboratory exams, diagnostic methods, medication during hospitalization, severity scores and prognosis were collected and analyzed. Student's t test and Mann-Whitney test were used to compare characteristics of survivors and non-survivors at a 90-day follow-up and cerebrospinal fluid (CSF) manifestations of cryptococcal meningitis. Multivariate Cox regression analysis was used to identify the independent risk factors for mortality. Kaplan-Meier curves were used to analyze patient survival. Receiver operating characteristic (ROC) curves were used to evaluate the different prognostic factors. Results The 30- and 90-day survival rates were 93.6% and 80.9%, respectively, in cirrhotic patients with cryptococcosis. Cryptogenic liver diseases [hazard ratio (HR) = 7.567, 95% confidence interval (CI): 1.616-35.428, P = 0.010], activated partial thromboplastin time (APTT) (HR = 1.117, 95% CI: 1.016-1.229, P = 0.022) and Child-Pugh score (HR = 2.146, 95% CI: 1.314-3.504, P = 0.002) were risk factors for 90-day mortality in cirrhotic patients with cryptococcosis. Platelet count (HR = 0.965, 95% CI: 0.94-0.991, P = 0.008) was a protective factor. APTT (HR = 1.12, 95% CI: 1.044-1.202, P = 0.002) and Child-Pugh score (HR = 1.637, 95% CI: 1.086-2.469, P = 0.019) were risk factors for 90-day mortality in cirrhotic patients with cryptococcal meningitis. There was significant difference in the percentage of lymphocytes in CSF between survivors and non-survivors [60.0 (35.0-75.0) vs. 95.0 (83.8-97.2), P < 0.001]. The model of end-stage liver disease-sodium (MELD-Na) score was more accurate for predicting 30-day mortality both in patients with cryptococcosis [area under curve (AUC): 0.826, 95% CI: 0.618-1.000] and those with cryptococcal meningitis (AUC: 0.742, 95% CI: 0.560-0.924); Child-Pugh score was more useful for predicting 90-day mortality in patients with cryptococcosis (AUC: 0.823, 95% CI: 0.646-1.000) and those with cryptococcal meningitis (AUC: 0.815, 95% CI: 0.670-0.960). Conclusions These results showed that cryptogenic liver diseases, APTT and Child-Pugh score were associated with mortality in cirrhotic patients with cryptococcosis and cryptococcal meningitis. MELD-Na score was important for predicting 30-day mortality, and Child-Pugh score was critical for predicting 90-day mortality.
Article
Full-text available
Purpose of Review Evaluate the epidemiology, risk factors, pathophysiology, and clinical outcomes of cryptococcal infections in patients with advanced liver disease or liver transplantation. Recent Findings Cryptococcal infections in patients with advanced liver disease (ALD) are uncommon but associated with high mortality. Less than 10% of patients in a prospective study of non-HIV-infected cryptococcal meningitis patients had ALD. Significantly, fever was uncommon, resulting in delays in diagnosis. Modalities for diagnosing cryptococcal infections include the rapid lateral flow cryptococcal antigen (CrAg) assay from serum and cerebrospinal fluid (CSF) specimens and multiplex polymerase chain reactions from CSF. Screening all ALD patients with CrAg has not been beneficial. Summary Cryptococcal infections in patients with ALD and liver transplantation result in poor outcomes due to diagnostic delays and concomitant impaired liver function with hepatotoxic therapies. A high index of suspicion is necessary as routine screening has very low yield for early detection.
Article
Full-text available
An 8-person subcommittee of the National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group evaluated available data on the treatment of cryptococcal disease. Opinion regarding optimal treatment was based on personal experience and information in the literature. The relative strength of each recommendation was graded according to the type and degree of evidence available to support the recommendation, in keeping with previously published guidelines by the Infectious Diseases Society of America (IDSA). The panel conferred in person (on 2 occasions), by conference call, and through written reviews of each draft of the manuscript. The choice of treatment for disease caused by Cryptococcus neoformans depends on both the anatomic sites of involvement and the host's immune status. For immunocompetent hosts with isolated pulmonary disease, careful observation may be warranted; in the case of symptomatic infection, indicated treatment is fluconazole, 200-400 mg/day for 36 months. For those individuals with non-CNS-isolated cryptococcemia, a positive serum cryptococcal antigen titer >1:8, or urinary tract or cutaneous disease, recommended treatment is oral azole therapy (fluconazole) for 36 months. In each case, careful assessment of the CNS is required to rule out occult meningitis. For those individuals who are unable to tolerate fluconazole, itraconazole (200-400 mg/day for 6-12 months) is an acceptable alternative. For patients with more severe disease, treatment with amphotericin B (0.5-1 mg/kg/d) may be necessary for 6-10 weeks. For otherwise healthy hosts with CNS disease, standard therapy consists of amphotericin B, 0.7-1 mg/kg/d, plus flucytosine, 100 mg/kg/d, for 6-10 weeks. An alternative to this regimen is amphotericin B (0.7-1 mg/kg/d) plus 5-flucytosine (100 mg/kg/d) for 2 weeks, followed by fluconazole (400 mg/day) for a minimum of 10 weeks. Fluconazole "consolidation" therapy may be continued for as along as 6-12 months, depending on the clinical status of the patient. HIV-negative, immunocompromised hosts should be treated in the same fashion as those with CNS disease, regardless of the site of involvement. Cryptococcal disease that develops in patients with HIV infection always warrants therapy. For those patients with HIV who present with isolated pulmonary or urinary tract disease, fluconazole at 200-400 mg/d is indicated. Although the ultimate impact from highly active antiretroviral therapy (HAART) is currently unclear, it is recommended that all HIV-infected individuals continue maintenance therapy for life. Among those individuals who are unable to tolerate fluconazole, itraconazole (200-400 mg/d) is an acceptable alternative. For patients with more severe disease, a combination of fluconazole (400 mg/d) plus flucytosine (100-150 mg/d) may be used for 10 weeks, followed by fluconazole maintenance therapy. Among patients with HIV infection and cryptococcal meningitis, induction therapy with amphotericin B (0.7-1 mg/kg/d) plus flucytosine (100 mg/kg/d for 2 weeks) followed by fluconazole (400 mg/d) for a minimum of 10 weeks is the treatment of choice. After 10 weeks of therapy, the fluconazole dosage may be reduced to 200 mg/d, depending on the patient's clinical status. Fluconazole should be continued for life. An alternative regimen for AIDS-associated cryptococcal meningitis is amphotericin B (0.7-1 mg/kg/d) plus 5-flucytosine (100 mg/kg/d) for 6-10 weeks, followed by fluconazole maintenance therapy. Induction therapy beginning with an azole alone is generally discouraged. Lipid formulations of amphotericin B can be substituted for amphotericin B for patients whose renal function is impaired. Fluconazole (400-800 mg/d) plus flucytosine (100-150 mg/kg/d) for 6 weeks is an alternative to the use of amphotericin B, although toxicity with this regimen is high. In all cases of cryptococcal meningitis, careful attention to the management of intracranial pressure is imperative to assure optimal c
Article
Full-text available
We conducted a case study of human immunodeficiency virus (HIV)-negative patients with cryptococcosis at 15 United States medical centers from 1990 through 1996 to understand the demographics, therapeutic approach, and factors associated with poor prognosis in this population. Of 306 patients with cryptococcosis, there were 109 with pulmonary involvement, 157 with central nervous system (CNS) involvement, and 40 with involvement at other sites. Seventy-nine percent had a significant underlying condition. Patients with pulmonary disease were usually treated initially with fluconazole (63%); patients with CNS disease generally received amphotericin B (92%). Fluconazole was administered to approximately two-thirds of patients with CNS disease for consolidation therapy. Therapy was successful for 74% of patients. Significant predictors of mortality in multivariate analysis included age ⩾60 years, hematologic malignancy, and organ failure. Overall mortality was 30%, and mortality attributable to cryptococcosis was 12%. Cryptococcosis continues to be an important infection in HIV-negative patients and is associated with substantial overall and cause-specific mortality.
Article
Full-text available
Limited data are available on the clinical significance of cryptococcaemia, which occurs in 10-30% of patients with cryptococcal diseases. To describe the clinical features of cryptococcaemia and identify its prognostic factors. Retrospective cohort study. All adult patients with Cryptococcus neoformans isolated from blood culture at the National Taiwan University Hospital, Taipei, 1981-2001, were included. Demographic and clinical information was obtained from medical records. Fifty-two patients were diagnosed and treated for cryptococcaemia. Acquired immunodeficiency syndrome (24/52, 46%), immunosuppressive therapy (12/52, 23%) and decompensated liver cirrhosis (11/52, 21%) were the three major predisposing conditions. Forty-two patients (81%, n=52) had sepsis, including four patients with septic shock, when blood cultures were obtained. Of the 38 patients in whom lumbar puncture was done, cerebrospinal fluid culture showed meningeal involvement in 32 (84%). The 30-day fatality rate was 37%. Liver cirrhosis, septic shock at presentation, an initial APACHE II score >/=20, age >/=60 years and female gender were associated with mortality under univariate analysis. Starting antifungal therapy within 48 h after blood culture was associated with improved survival. Under multivariate analysis, liver cirrhosis remained a strong independent predictor of mortality at 30 days after blood culture (HR 16.3, 95%CI 2.6-101.7, p=0.003). Patients with cryptococcaemia have a high risk of mortality within 30 days. Sepsis and meningeal involvement are common. Those with liver cirrhosis have a particularly poor prognosis.
Article
Background: Limited data are available on the clinical significance of cryptococcaemia, which occurs in 10–30% of patients with cryptococcal diseases. Aim: To describe the clinical features of cryptococcaemia and identify its prognostic factors. Study design: Retrospective cohort study. Methods: All adult patients with Cryptococcus neoformans isolated from blood culture at the National Taiwan University Hospital, Taipei, 1981–2001, were included. Demographic and clinical information was obtained from medical records. Results: Fifty‐two patients were diagnosed and treated for cryptococcaemia. Acquired immunodeficiency syndrome (24/52, 46%), immunosuppressive therapy (12/52, 23%) and decompensated liver cirrhosis (11/52, 21%) were the three major predisposing conditions. Forty‐two patients (81%, n =52) had sepsis, including four patients with septic shock, when blood cultures were obtained. Of the 38 patients in whom lumbar puncture was done, cerebrospinal fluid culture showed meningeal involvement in 32 (84%). The 30‐day fatality rate was 37%. Liver cirrhosis, septic shock at presentation, an initial APACHE II score ≥20, age ≥60 years and female gender were associated with mortality under univariate analysis. Starting antifungal therapy within 48 h after blood culture was associated with improved survival. Under multivariate analysis, liver cirrhosis remained a strong independent predictor of mortality at 30 days after blood culture (HR 16.3, 95%CI 2.6–101.7, p =0.003). Discussion: Patients with cryptococcaemia have a high risk of mortality within 30 days. Sepsis and meningeal involvement are common. Those with liver cirrhosis have a particularly poor prognosis.
Article
Cryptococcus neoformans is a widely distributed saprophytic fungus that may cause opportunistic infections in normal and immunocompromised individuals particularly in patients with HIV infection. Disseminated infection in HIV-negative individuals is occasionally seen: a 57-year-old HIV-negative Turkish female initially presented with enlarged mediastinal lymph nodes and a large pulmonary parenchymal nodule, eventually diagnosed with disseminated cryptococcosis and tuberculosis.
Article
In the absence of coexisting HIV infection Cryptococcus neoformans is rarely considered in the differential diagnosis of peritonitis that occurs in patients with cirrhosis and ascites. Here, we report on a 39–year–old male, HIV–negative patient with decompensated alcohol toxic liver cirrhosis who developed a lethal intraperitoneal infection with C. neoformans. We reviewed the literature and found an additional 19 cases with culture confirmed cryptococcal peritonitis in combination with liver disease or AIDS. We suggest that awareness of this unusual but lethal entity may lead to earlier diagnosis and proper treatment.
Article
To describe the clinical characteristics, treatment, and outcomes of cryptococcosis in HIV-negative patients. HIV-negative adult patients with positive culture for Cryptococcus neoformans who attended Ramathibodi Hospital between 1987 and 2003 were retrospectively reviewed. During the 17 year review period, 40 HIV-negative patients with cryptococcosis were identified. Of these, 37 patients had medical records available for study. The mean age was 49+/-18 (range 16-83) years and 73% were female. Twenty-four patients (65%) had associated underlying conditions. The most common associated conditions included immunosuppressive drug treatment (41%), presence of systemic lupus erythematosus (16%), malignancies (16%), and diabetes mellitus (14%). C. neoformans was mainly recovered from cerebrospinal fluid (32%), blood (28%), and sputum/bronchoalveolar lavage/lung tissue (28%). Twenty-three patients (62%) had disseminated cryptococcosis. Six of 14 patients with cryptococcal meningitis were asymptomatic. About half of the patients were treated with amphotericin B and subsequent fluconazole. Five patients (14%) were initially misdiagnosed and treated for tuberculosis or bacterial infection. The overall mortality rate was 27%. Cryptococcosis is not rare in HIV-negative patients. The mortality rate is high. Early recognition of cryptococcosis and use of appropriate antifungal therapy in these patients may improve clinical outcomes.
Article
Cryptococcal meningitis has emerged as a leading cause of infectious morbidity and mortality in patients with AIDS. Among the human immunodeficiency virus (HIV)-seropositive subjects, cryptococcal meningitis is the second most common cause of opportunistic neuro-infection. Current trends are changing due to the marked improvement of quality and length of life produced by highly active antiretroviral therapy (HAART). The introduction of generic HAART in India has resulted in an increase in the number of individuals getting treatment for HIV infection, as the cost of highly active antiretroviral therapy (HAART) has decreased 20- fold. Cryptococcal meningitis occurs in non-HIV patients who are immunodeficient due to diabetes, cancer, solid organ transplants, chemotherapeutic drugs, hematological malignancies etc and rarely in healthy individuals with no obvious predisposing factors. Diagnosis of cryptococcal meningitis is fairly straightforward once the diagnosis is considered in the differential diagnosis of chronic meningitis. Treatment of a patient with cryptococcal infection is a challenge for both the physician and the patient, but rewarding, as many would recover with timely and adequate antifungal therapy.